OUR SITES: corporate.clinuvel.com | photoprotection.clinuvel.com | clinuvel.com

Company Activities People Governance Business Development Path to Market Intellectual Property Products Clinical Applications Work Opportunities

Home Corporate Investors FAQ's Contact Photoprotection

Home > Corporate > Business Development

Business Development

We are advancing the program of afamelanotide (CUV1647) and are currently in Phase III trials.

2008 Annual Report